Profarma Distribuidora de Produtos Farmacêuticos S.A

What it is

Founded in 1961, Grupo Profarma is one of Brazil’s largest pharmaceutical groups; its distribution arm is the country’s second-largest, supplying more than 50,000 pharmacy clients a month and reaching over 4,500 cities. The retail arm, Rede d1000, runs more than 300 stores under the Drogasmil, Farmalife, Tamoio, and Rosário banners, serving over 2.5 million customers a month across Rio de Janeiro, the Federal District, and Mato Grosso.

In 2006, Profarma became the first Brazilian pharmaceutical distributor to list on the stock exchange. The group’s three legs — bulk distribution, retail pharmacy, and now specialty medicines — make it the most diversified listed pharma company in Brazil.

Who owns it

The largest single shareholder is Cencora, Inc. (the US pharmaceutical giant formerly known as AmerisourceBergen), which holds 39% of shares outstanding. A private company — linked to the founding Birmarcker family — holds a further 26%.

Together, insiders and associated companies control roughly 66% of the share capital (EODHD), leaving a free float of around one-third.

Manoel Birmarcker is the company’s founder, and the family retains deep operational involvement: Deborah Birmarcker serves as ESG director of the group. The general public — individual investors — hold about 16% of the stock.

Who runs it

Sammy Birmarcker is Chief Executive Officer — founder Manoel’s successor and the face of the group’s acquisition strategy. He personally holds about 1.1% of shares outstanding, aligning his interests directly with those of other shareholders.

A CFO is not separately disclosed in available sources.

The money, in plain words

Profarma is a high-volume, thin-margin business: it keeps less than 1 cent of profit on every real of sales — a net profit margin of roughly 0.9% (EODHD TTM), which is exactly where pharmaceutical wholesalers worldwide sit. Revenue has grown 32% in two years, from R$8.66bn (US$1.7 bn) in 2023 to R$11.45bn (US$2.2 bn) (~$2.22bn) in FY2025 — a compound annual growth rate of about 15% (our calculation).

For every real that shareholders own in the business, it earns about 9 cents a year — a return on equity of 7–9%, modest but rising as margins recover. The company carries net debt of R$1.17bn (US$227 mn) (~$227m), about 87% of its stock market value, which is the main financial risk to watch.

At a price-to-earnings ratio of 7.6×, the market is pricing it cheaply by any historical standard — reflecting both the debt load and the integration risk of its latest deal.

What it is doing now

On 4 May 2026, Profarma completed the acquisition of 100% of 4Bio Medicamentos, Brazil’s specialty-medicines distributor, through its subsidiary Health Ventures. The purchase price was R$600m (US$117 mn) (~$116m), paid to RD Saúde.

The deal is the largest in Profarma’s history and marks its return to the specialty segment five years after selling its previous specialty unit.

4Bio, founded in 2004, focuses on high-complexity medicines for patients, hospitals, clinics, and health insurers; in the twelve months to September 2025 it posted revenue of R$3.4bn (US$660 mn), growing at an average 15% a year since 2023. Profarma will pay in six instalments of R$100m (US$19 mn), with the remaining five corrected by the CDI rate over five years.

What to watch

• Debt after 4Bio: The acquisition adds R$600m (US$117 mn) in staged payments onto a balance sheet that already carries R$1.17bn (US$227 mn) in net debt; how quickly cash generation covers this will define the investment case.
• Specialty margin uplift: Profarma says the specialty segment offers higher average ticket sizes, potentially stronger margins, and structural demand driven by population ageing and new medical technologies. Whether that flows through to group margins is the key earnings test.
• Cencora’s strategic role: With 39% of the company, Cencora is more than a passive investor; any shift in that relationship — deeper integration or a stake sale — would move the stock materially.
• Revenue growth sustainability: Profarma Distribution already serves more than 50,000 pharmacy clients across Brazil. Further organic growth depends on Brazil’s pharmaceutical market expanding, which has been running well above GDP growth.

This is news, not investment advice.